‘Clinical Diabetology’: Highlights of 2024 and Thank You to Our Reviewers

Abstract

Not available

Greetings from the Editorial Board of ‘Clinical Diabetology’!

The year 2024 was the third for ‘Clinical Diabetology’ (CD) under the Editor-in-Chief, Dr. Viral N. Shah and his Editorial team. In a way, it is our duty to share some of our recent achievements and insights with readers of the Journal. We continue to see an increase in submissions to ‘Clinical Diabetology’ from around the world. Compared to 2024, both the number of submissions as well as acceptances to CD have grown by 20%, while the rejection rate has been stable at around 40%. Despite this increment, the Editors were able to keep the average ‘submission to early publication’ time below 100 days and our goal is to reduce time from ‘acceptance to early publication’ (Fig. 1).

Figure 1. Average Time from Article Submission to Approval and Early Publication

The numbers of both downloads and views of articles published in CD are growing. Table 1 highlights the top three most downloaded research articles in the year 2024. Along with these trends, we have good reasons to expect growth of two crucial bibliometric parameters, i.e., Impact Factor by Clarivate Analytics and CiteScore by the Scopus database.

Table 1. Top Three Most Downloaded Articles Published in 2024 Issues (as of February 13th, 2025)

Issue	Title	First author	Number of views	Reference
2024;1	A Practical Approach to the Initiation, Titration and Intensification of Insulin Therapy in Adults with Diabetes in the Indian Context: Recommendations by Association of Clinical Endocrinologists Consensus Group	Erukulapati RS	842	[1]
2024;2	Self-Care Management and Glycemic Control Among Patients with Type 2 Diabetes in Bahrain: A Cross-Sectional Study	Al Ubaidi BAA	613	[2]
2024;1	Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp) vs. Insulin Glargine (IGlarU300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study	Hasnani D	566	[3]

Additionally, at the end of 2024, CD joined ResearchGate, which we believe will enhance its visibility and circulation. Achieving this progress would not have been possible without contributions of expert reviewers helping us select the best research articles. We would like to extend our thanks to all active reviewers but especially highlight the five experts who were most active in 2024:

• Edward Franek — Department of Internal Medicine, Endocrinology, and Diabetology, MSWiA, Warsaw, Poland
• Vinod Abichandani — MSc Endocrinology, University of South Wales, United Kingdom
• Vipul Chavda — Rudraksha Institute of Medical Sciences, Gujarat, India
• Dhruvi Hasnani — Department of Diabetology, Rudraksh Institute of Medical Sciences, Ahmedabad, Gujarat, India
• Kaumudi Chenamsetti — Diahappy Diabetes Reversal Clinic, Shyamal, Vastrapur Ahmedabad, India

We wish you all a very happy, healthy, and prosperous 2025! We invite you to join forces with us by submitting your research contributions, citing our scientific research articles and contributing as a reviewer.

Conflict of interest

Dr. Shah is the Editor-in-Chief for ‘Clinical Diabetology’. Dr. Shah’s institute has received research support from Dexcom, Zucara Therapeutics, Enable Bioscience, Eli Lilly, Cystic Fibrosis Foundation, Breakthrough T1D, and NIH. Dr. Shah reports receiving personal fees from Sanofi, Eli Lilly, NovoNordisk, Dexcom, Ascensia Diabetes Care, Insulet, Tandem Diabetes Care, Biomea Fusion, Sequel Med Tech, Genomelink, and Lumosfit for consulting, advising, or speaking, outside of this work.

Dr. Stolarczyk is a consultant advisor to Via Medica, publisher of scientific journals, including ‘Clinical Diabetology’.